Earkart Makes Modest Debut with 5.37% Premium, Lists at ₹142.25 Against Weak Subscription

Earkart Limited, the HealthTech platform specialising in hearing aids and related accessories with Shop-in-Shop franchise model, made a modest debut on BSE SME on October 3, 2025. After closing its IPO bidding between September 25-29, 2025, the company commenced trading with a 0.37% premium opening at ₹135.50 and rose to ₹142.25 with gains of 5.37%, reflecting cautious investor sentiment towards the healthtech sector backed by weak subscription response.

Earkart Listing Details

Earkart Limited launched its IPO at ₹135 per share with a minimum investment of 2,000 shares costing ₹2,70,000. The IPO received a weak response with a subscription of just 1.28 times - individual investors at extremely poor 0.35 times and NII at a modest 1.63 times, indicating severe lack of investor confidence especially among retail participants in the hearing aids distribution business.

First-Day Trading Performance Outlook

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

• Listing Price: Earkart share price opened at ₹135.50, representing a premium of 0.37% from the issue price of ₹135, and rose to ₹142.25, delivering gains of 5.37% for investors, reflecting cautious market sentiment toward the healthtech sector.

Growth Drivers and Challenges

Growth Drivers:

• Diversified Distribution Network: Multi-channel approach spanning online, offline, and B2G sales as a trusted GeM supplier to ALIMCO, plus an innovative Shop-in-Shop franchise model with 49 SIS clinics across 22 cities in 6 states and 2 Union Territories.
• Comprehensive Product Portfolio: Wide range of hearing aids, including RIC, IIC, BTE, ITE, ITC, and CIC devices, plus adjustable foldable walkers and MSIED/TLM products forthe  physically challenged, serving diverse customer segments.
• Strong Financial Performance: Exceptional PAT growth of 125% to ₹6.88 crore and revenue growth of 35% to ₹43.19 crore in FY25, impressive ROE of 34.55%, strong ROCE of 47.32%, and healthy margins with PAT margin of 15.93% and EBITDA margin of 22.65%.

Challenges:

• Extremely Poor Market Reception: Disastrous subscription of just 1.28 times with retail participation at an alarming 0.35 times, reflecting severe investor scepticism about business model sustainability despite modest listing gain of 5.37%.
• Aggressive Valuation Concerns: Post-issue P/E of 26.98x and elevated price-to-book value of 7.08x reflecting premium valuation with bumper FY25 results raising sustainability questions and appearing aggressively priced for the SME segment.
• Small Scale Operations: Limited operational scale with ₹43.19 crore revenue, manufacturing facility of just 4,500 square feet in Noida, and relatively nascent SIS franchise model launched in April 2024, raising scalability concerns.

Utilisation of IPO Proceeds

• Working Capital Requirements: ₹21.10 crore for funding incremental working capital requirements supporting inventory management, business expansion, and operational scale-up across the hearing aids distribution business.
• Business Expansion: ₹17.33 crore for capital expenditure for setting up Shop-in-Shop business model in ENT/Ophthalmic clinics across India, and infrastructure for operational activities expanding franchise network.
• General Corporate Purposes: ₹0.63 crore supporting business operations and strategic initiatives for sustained growth in the competitive healthtech and hearing aids segment.

Financial Performance of Earkart

• Revenue: ₹43.19 crore for FY25, showing solid growth of 35% from ₹31.97 crore in FY24, reflecting strong market demand and successful business scaling in hearing aids distribution.
• Net Profit: ₹6.88 crore in FY25, representing exceptional growth of 125% from ₹3.06 crore in FY24, indicating substantial operational leverage, though bumper results raise sustainability questions requiring careful monitoring.
• Financial Metrics: Impressive ROE of 34.55%, strong ROCE of 47.32%, low debt-to-equity ratio of 0.26, healthy PAT margin of 15.93%, solid EBITDA margin of 22.65%, and estimated market capitalisation of ₹195.65 crore.